Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

H Wiendl, R Gold, T Berger, T Derfuss… - Therapeutic …, 2021 - journals.sagepub.com
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous
system characterized by inflammatory demyelination and axonal/neuronal damage. The …

Multiple sclerosis: inflammatory and neuroglial aspects

G Papiri, G D'Andreamatteo, G Cacchiò, S Alia… - Current Issues in …, 2023 - mdpi.com
Multiple sclerosis (MS) represents the most common acquired demyelinating disorder of the
central nervous system (CNS). Its pathogenesis, in parallel with the well-established role of …

Prediction of disease progression and outcomes in multiple sclerosis with machine learning

MF Pinto, H Oliveira, S Batista, L Cruz, M Pinto… - Scientific reports, 2020 - nature.com
Multiple Sclerosis is a chronic inflammatory disease, affecting the Central Nervous System
and leading to irreversible neurological damage, such as long term functional impairment …

Addressing the challenges and barriers to the integration of machine learning into clinical practice: An innovative method to hybrid human–machine intelligence

C Ed-Driouch, F Mars, PA Gourraud, C Dumas - Sensors, 2022 - mdpi.com
Machine learning (ML) models have proven their potential in acquiring and analyzing large
amounts of data to help solve real-world, complex problems. Their use in healthcare is …

Building digital patient pathways for the management and treatment of multiple sclerosis

J Wenk, I Voigt, H Inojosa, H Schlieter… - Frontiers in …, 2024 - frontiersin.org
Recent advances in the field of artificial intelligence (AI) could yield new insights into the
potential causes of multiple sclerosis (MS) and factors influencing its course as the use of AI …

[HTML][HTML] Is benign MS really benign? What a meaningful classification beyond the EDSS must take into consideration

D Ellenberger, P Flachenecker, J Haas… - Multiple Sclerosis and …, 2020 - Elsevier
Background Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative disease
with an unpredictable course that has a broad clinical spectrum and progresses over time. If …

[HTML][HTML] Cognitive impairment, fatigue and depression in multiple sclerosis: Is there a difference between benign and non-benign MS?

H Bogaardt, D Golan, MA Barrera, S Attrill… - Multiple sclerosis and …, 2023 - Elsevier
Abstract Introduction Multiple Sclerosis (MS) is a chronic inflammatory and degenerative
disease of the central nervous system (CNS). The severity of disability in people with MS …

Performance of administrative databases for identifying individuals with multiple sclerosis

P Ducatel, M Debouverie, M Soudant, F Guillemin… - Scientific Reports, 2023 - nature.com
Administrative databases are an alternative to disease registries as a research tool to study
multiple sclerosis. However, they are not initially designed to fulfill research purposes …

Neurocognitive impairment and social cognition in multiple sclerosis

T Doskas, GD Vavougios, P Karampetsou… - International Journal …, 2022 - Taylor & Francis
Purpose/aim of the study The impairment of neurocognitive functions occurs in all subtypes
of multiple sclerosis, even from the earliest stages of the disease. Commonly reported …

[HTML][HTML] Fatigue and health-related quality of life depend on the disability status and clinical course in RRMS

H Ahvenjärvi, M Niiranen, S Simula… - Multiple sclerosis and …, 2023 - Elsevier
Background Fatigue is a prominent and disabling symptom of multiple sclerosis (MS),
impairing quality of life. The disease course of relapsing remitting MS (RRMS) is individual …